Traditional Chinese medicinal composition for treating stagnant-pathogen-of-shaoyang type lung cancer hydrothorax

Abstract

The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicinal composition for treating stagnant-pathogen-of-shaoyang type lung cancer hydrothorax. The traditional Chinese medicinal composition comprises, by weight, 4-8 parts of Mariscus Compactus, 4-8 parts of Syringa Reticulata, 4-8 parts of Saussurea Hieracioides, 4-8 parts of Radix Knoxiae, 4-8 parts of ginkgo roots, 4-8 parts of Aechmanthera Tomentosa, 4-8 parts of Rhizoma Junci Amplifolii, 4-8 parts of Russula Virescens and 4-8 parts of glycyrrhiza. The traditional Chinese medicinal composition has the advantages that the effect of freeing lung-qi, eliminating dampness, strengthening body resistance and eliminating pathogenic factors is achieved through combination of the herbs, the lung cancer hydrothorax can be reduced obviously, and life quality of patients can be improved.

Description

Technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to a traditional Chinese medicine composition for treating pleural effusion of lung cancer with evil depression and shaoyang type. Background technique [0002] Pleural effusion of lung cancer is one of the most common complications of advanced lung cancer. The average survival time is 3.1±0.5 months, the mortality rate within 1 month is 5.4%, and the mortality rate within 6 months is 84%. Because of its stubbornness and serious impact The patient's quality of life and survival time. The current treatments mainly include systemic chemotherapy and local pleural infusion chemotherapy, which have serious side effects and are difficult for many advanced patients to accept. Therefore, controlling pleural effusion, alleviating symptoms, and improving quality of life are the main goals of treating advanced lung cancer with pleural effusion. Therefore, the study of lung cancer pleur...

AI Technical Summary

Problems solved by technology

[0003] Lung cancer pleural effusions are mostly late-stage cancers, and the opportunity for surgical treatment is lost. Clinically, medical palliative care is mainly used to relieve symptoms and relieve pain. However, systemic chemotherapy and local pleural perfusion chemotherapy for the primary tumor are difficult to control pleural effusion, and the side effects are large. Simple pleural puncture can temporarily relieve symptoms, but the fluid can quickly reassemble, and repeated aspiration will consume protein and immune cells, making the patient's body weaker and weaker, and hypoproteinemia can aggravate the reassembly of pleural effusion At the same time, it can also lead to effusion parcels, and even half of the patients are complicated by infection to make the disease progress. Therefore, only by pumping pleural effusion, systemic and local chemotherapy can not solve the reunion of pleural effusion, and the curative effect is very unsatisfactory. Physical strength is exhausting, which significantly reduces the physical fitness of cancer patients, affecting the survival period and quality of life of patients

[0004] Xieyu Shaoyang type is a common type of lung cancer pleural effusion, and there is no specific drug for this type of lung cancer pleural effusion